MOUNTAINSIDE, NJ--(Marketwire -09/28/11)- PROTEONOMIX, INC. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has made substantial progress in arranging the clinical trial of its stem cell treatment for patients awaiting liver transplant to overcome End Stage Liver Disease ("ESLD"). |
MOUNTAINSIDE, NJ--(Marketwire -09/06/11)- PROTEONOMIX, INC. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced that Michael Cohen, Chief Executive Officer of Proteonomix and Ian McNiece, the Company's Chief Scientific Officer met today with the team at Gilford Securities, the Company's Investment Banker, and Aegis Capital. |
